Healthcare & Life Sciences·南北アメリカ·2023
世界をリードするバイオ製薬企業
0%
ピーク収益到達の短縮
$0B
維持された既存収益
0mo
計画前倒し
Back to Our Work
課題
主力2製品の特許切れに直面し、新世代腫瘍領域の発売を加速しつつ、30市場で成熟ブランドの残存収益を最大化する必要があった。
アプローチ
We redesigned the go-to-market model around omnichannel engagement, deploying AI-driven physician targeting and next-best-action engines. We restructured the commercial organization from geography-based to therapeutic-area-aligned teams and built a launch excellence playbook that reduced time-to-peak-revenue by 40%.
インパクト
The first new therapy launched reached peak-year revenue projections 18 months ahead of plan. Legacy brand managed decline was slowed by 25%, preserving $1.2 billion in cumulative revenue over three years.